The Intermediate Uveitis drugs in development market research report provides comprehensive information on the therapeutics under development for Intermediate Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Intermediate Uveitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Intermediate Uveitis and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Intermediate Uveitis by eight companies/universities/institutes. The top development phase for Intermediate Uveitis is preclinical with three drugs in that stage. The Intermediate Uveitis pipeline has eight drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Intermediate Uveitis pipeline products market are: Eyevensys, Pharmapraxis and Novartis.
The key targets in the Intermediate Uveitis pipeline products market include Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2), Neuropilin 1 (Vascular Endothelial Cell Growth Factor 165 Receptor or CD304 or NRP1), and Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2).
The key mechanisms of action in the Intermediate Uveitis pipeline product include Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor with one drug in Preclinical. The Intermediate Uveitis pipeline products include six routes of administration with the top ROA being Intravitreal and five key molecule types in the Intermediate Uveitis pipeline products market including Monoclonal Antibody, and Small Molecule.
Intermediate Uveitis overview
Intermediate uveitis is a type of uveitis, which is an inflammation of the uvea, the middle layer of the eye. Intermediate uveitis specifically involves inflammation in the vitreous, a gel-like substance in the middle of the eye and lead to the formation of inflammatory cells and debris in the vitreous. Symptoms include floaters, blurred vision, eye pain and redness. Diagnosis includes comprehensive eye examination and ancillary tests, such as optical coherence tomography (OCT) and fluorescein angiography, used to assess the extent of inflammation and its impact on the retina.
For a complete picture of Intermediate Uveitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
